Upstart cancer drug developer Aura Biosciences has rounded up $21 million for its Series B, attracting a large group of backers and keeping former Genzyme CEO and ubiquitous biotech investor Henri Termeer in the game.
Harvard chemistry professor Andrew Myers says he's made a breakthrough that can greatly expand a class of antibiotics, forming the foundation for his latest startup: Macrolide Pharmaceuticals. And the biotech is launching today with $22 million in venture cash from an impressive group of venture backers.
For more than a year now, NEA general partner David Mott has helmed Mersana Therapeutics, a Cambridge, MA-based biotech that has been working on next-gen antibody-drug conjugates. But this morning he's handing the reins over to longtime biotech vet Anna Protopapas (while remaining chairman) after organizing a $35 million B round that will be announced later this morning.
Israeli-American biotech Chiasma has raised $70 million in Series E cash, moving on from an aborted collaboration with Roche and rolling toward FDA approval with a treatment for the hormone disorder acromegaly.
Eccrine Systems has raised $1.5 million in seed funding to develop a sweat sensor based on know-how that originated at the University of Cincinnati and the Air Force Research Labs. The Cincinnati, Ohio-based startup will use the cash to forge ahead with the development of wearable sensor technology it plans to pitch to clinical trial sponsors.
Novo Nordisk has set the terms for the IPO of its IT services unit NNIT. If NNIT prices at the top end of its range when it goes public in the next week or so, the listing could generate up to $335 million for Novo Nordisk.
Months after a bitter exit from the top spot at Sanofi, Christopher Viehbacher is back out in public, joining Boston startup factory PureTech to help steer its portfolio of fledgling companies.
South San Francisco's Lyric Pharmaceuticals raised $20.4 million in first-round financing to support its work on a hush-hush gastrointestinal drug.
If anyone had doubts about exactly where Neil Woodford was going to aim the brunt of his new £200 million ($300 million) fund, details of the board that will oversee the venture will have washed away the uncertainty.
Texas-based Neos Therapeutics has rounded up $20.6 million to bankroll their late-stage regulatory work on extended-release formulations of a slate of ADHD drugs that is now being served up to regulators for review.